Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 32.06% | 3.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.47% | 9.97% | |||
| Operating Income | -19.47% | -9.97% | |||
| Income Before Tax | -23.48% | -12.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.48% | -12.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.48% | -12.60% | |||
| EBIT | -19.47% | -9.97% | |||
| EBITDA | -19.68% | -10.09% | |||
| EPS Basic | -22.88% | -12.03% | |||
| Normalized Basic EPS | -22.91% | -11.99% | |||
| EPS Diluted | -22.88% | -12.03% | |||
| Normalized Diluted EPS | -22.91% | -11.99% | |||
| Average Basic Shares Outstanding | 0.49% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.49% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||